Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reformulated Zicam Nasal Swabs Return Matrixx To Top Sales Category

This article was originally published in The Tan Sheet

Executive Summary

Matrixx Initiatives re-launches Zicam Cold Remedy Nasal Swabs with “plant-based ingredients” replacing the original product’s zinc gluconate. Consumer trust in the Zicam brand prompted the reformulation and re-launch, says CEO M’lou Walker.

You may also be interested in...



Zinc, Vitamin C Don't Reduce COVID-19 Symptoms; Impact On Shortening Colds Not Questioned

Trial with 214 adults with SARS-CoV-2 showed no significant difference among the treatment groups in number of days to symptom relief. Study didn’t measure zinc/vitamin C supplementation for shortening duration of colds.

Supplement Claims On Duration Of Cold, Menopausal Support Fail In UK Reviews

The Advertising Standards Authority says Swedish firm Enymatica misses the mark for supporting ColdZyme supplement claims and UK firm PharmaCare’s ads for the Promensil menopause symptoms supplement run afoul of the rule it cites as support.

Zicam Creates A Monster With Reanimated Brand

Matrixx aims to make more consumers aware they can shorten the duration of a cold rather than treat the symptoms without affecting how long the cold lasts. New advertising introduces the “Cold Monster” to remind consumers to use Zicam products when they feel the first signs of a “monster of a cold.”

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS108010

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel